Drugs for Recurrent Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 72)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
4659387 5311101 |
Synonyms:
ADVAIR
Advair®|Avamys®|Flovent HFA®|Veramyst®
FLOVENT HFA
Fluticason
|
Fluticasona
Fluticasone
Fluticasonum
VERAMYST
|
|
2 |
|
Selegiline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
14611-51-9, 14611-52-0 |
5195 26757 |
Synonyms:
(−)-selegiline
Apo-Selegiline
Bristol myers squibb brand OF selegiline
Bristol-myers squibb brand OF selegiline
Carbex
CENTRAPRYL 10
CENTRAPRYL 5
Deprenalin
Deprenil
Deprenyl
Eldepryl
Eldepryl®|L-deprenalin|Otrasel®|Selegene®|Zelapar®
Emsam
ENSAM
Gen-Selegiline
Humex
Hydrochloride, selegiline
Jumex
L-Deprenalin
L-Deprenyl
Novo-Selegiline
Nu-Selegiline
Sd Deprenyl
|
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
SELEGILINE
SELEGILINE HCL
Selegiline hydrochloride
Selegiline hydrochloride, (R)-isomer
Selegiline hydrochloride, (R,S)-isomer
Selegiline hydrochloride, (S)-isomer
Selegiline valeant brand
Selegiline, (R)-isomer
Selegiline, (R,S)-isomer
Selegiline, (S)-isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
STILLINE 10
STILLINE 5
Valeant brand OF selegiline
VIVAPRYL
Yumex
Zelapar
|
|
3 |
|
Varenicline |
Approved, Investigational |
Phase 4 |
|
249296-44-4 |
5310966 |
Synonyms:
6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine
Champix
Champix®|Chantix®|compound 9a [PMID: 16171993]|CP 526555
Chantix
CP-526,555
|
CP-526555
Tartrate, varenicline
Vareniclina
VARENICLINE
Varenicline tartrate
Vareniclinum
|
|
4 |
|
Hormones |
|
Phase 4 |
|
|
|
5 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
6 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
7 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
8 |
|
Fluticasone-Salmeterol Drug Combination |
|
Phase 4 |
|
|
|
9 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
10 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
11 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
13 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
14 |
|
Xhance |
|
Phase 4 |
|
|
|
15 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
16 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
17 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
18 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
19 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
20 |
|
Salmeterol Xinafoate |
|
Phase 4 |
|
94749-08-3 |
|
Synonyms:
GR-33343 G
GR-33343-G
GR-33343X
LIPO-202
|
SALMETEROL 1-HYDROXY-2-NAPHTHOATE
SALMETEROL XINAFOATE
SEREVENT
|
|
21 |
|
Protective Agents |
|
Phase 4 |
|
|
|
22 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
23 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
24 |
|
Monoamine Oxidase Inhibitors |
|
Phase 4 |
|
|
|
25 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
26 |
|
Nicotinic Agonists |
|
Phase 4 |
|
|
|
27 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
28 |
|
Modafinil |
Approved, Investigational |
Phase 2, Phase 3 |
|
68693-11-8 |
4236 |
Synonyms:
2-((Diphenylmethyl)sulfinyl)acetamide
2-((R)-(Diphenylmethyl)sulfinyl)acetamide
2-[(Diphenylmethyl)sulphinyl]acetamide
Alertec
Armodafinil
Benzhydrylsulfinylacetamide
CEP-1538
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
CRC-40476
CRL-40476
Dea No. 1680
DEP-1538
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
Modafinil
|
Modafinil [Usan:Inn]
MODAFINIL CIV
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Nuvigil
Provigil
Provigil®
R Modafinil
R-Modafinil
Sparlon
THN102 COMPONENT MODAFINIL
THN-102 COMPONENT MODAFINIL
Vigil
|
|
29 |
|
Methylphenidate |
Approved, Investigational |
Phase 2, Phase 3 |
|
113-45-1 |
4158 |
Synonyms:
4311/B Ciba
alpha-Phenyl-2-piperidineacetate methyl ester
alpha-Phenyl-2-piperidineacetic acid methyl ester
a-Phenyl-2-piperidineacetate methyl ester
a-Phenyl-2-piperidineacetic acid methyl ester
Calocain
Celltech brand OF methylphenidate hydrochloride
Centedein
Centedrin
Centedrine
Centredin
Cephalon brand OF methylphenidate hydrochloride
Concerta
Concerta®|Jornay PM® (a.k.a. HLD200)|Ritalin®
COTEMPLA XR-ODT
Daytrana
D-Methylphenidate HCL
Equasym
Focalin
Focalin XR
Hydrochloride, methylphenidate
Mallinckrodt brand OF methylphenidate hydrochloride
Meridil
Metadate
Metadate CD
Metadate ER
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetic acid
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl alpha-phenyl-alpha-2-piperidinylacetic acid
Methyl a-phenyl-a-(2-piperidyl)acetate
Methyl a-phenyl-a-(2-piperidyl)acetic acid
Methyl a-phenyl-a-2-piperidinylacetate
Methyl a-phenyl-a-2-piperidinylacetic acid
Methyl phenidyl acetate
Methyl phenidylacetate
Methyl phenidylacetic acid
methyl phenyl(piperidin-2-yl)acetate
Methyl phenyl(piperidin-2-yl)acetic acid
|
Methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetic acid
Methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetic acid
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate HCL
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidic acid
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MPH
Novartis brand 1 OF methylphenidate hydrochloride
Novartis brand 2 OF methylphenidate hydrochloride
Phenidylate
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin hydrochloride
Ritalin LA
Ritalin SR
Ritaline
Ritalin-SR
Ritcher Works
Tsentedrin
Α-phenyl-2-piperidineacetate methyl ester
Α-phenyl-2-piperidineacetic acid methyl ester
|
|
30 |
|
Dopamine |
Approved |
Phase 2, Phase 3 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
31 |
|
Sodium citrate |
Approved, Investigational |
Phase 2, Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
32 |
|
Sodium oxybate |
Approved |
Phase 3 |
|
502-85-2 |
23663870 |
Synonyms:
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
NSC-84223
OXYBATE SODIUM
SODIUM OXYBATE
|
SODIUM OXYBUTYRATE
WY-3478
XYREM
|
|
33 |
|
Esreboxetine |
Approved, Experimental, Investigational |
Phase 3 |
|
98769-81-4, 71620-89-8, 98819-76-2 |
65856 |
Synonyms:
(+)-(2S)-2-((S)-(2-Ethoxyphenoxy)phenylmethyl)morpholine
(S,S)-REBOXETINE
(SS)-Reboxetine
2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate
EDRONAX
Edronax®|PNU-165442G
|
Esreboxetine
PNU-165442G
Reboxetina
Reboxetine
Reboxetine mesylate
Vestra
|
|
34 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
35 |
|
Central Nervous System Stimulants |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Phosphodiesterase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Dopamine Uptake Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Dopamine Agents |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Anesthetics, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Anesthetics, General |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Anesthetics |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Citrate |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
44 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
45 |
|
Flumazenil |
Approved |
Phase 1, Phase 2 |
|
78755-81-4 |
3373 |
Synonyms:
[<sup>11</sup>C]flumazenil (PET ligand)
Anexate
Anexate®|Ro15-1788
Anexic acid
FLUMAZENIL
Flumazenilo
Flumazenilum
Flumazepil
Hoffman la roche brand OF flumazenil
Hoffman-la roche brand OF flumazenil
|
Lanexat
MAZICON
RO15-1788
RO-151788
RO-15-1788
RO-151788000
RO-1722
RO-41-8157
Roche brand OF flumazenil
Romazicon
|
|
46 |
|
Mirtazapine |
Approved |
Phase 2 |
|
85650-52-8, 61337-67-5 |
4205 |
Synonyms:
(N-Methyl-11C)mirtazapine
(S)-Mirtazapine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
2-METHYL-1,2,3,4,10,14B-HEXAHYDROPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE
6 Azamianserin
6-Azamianserin
Avanza
Axit
Celltech brand OF mirtazapine
Esmirtazapine
Mepirzapine
Mepirzepine
Mirtabene
Mirtaz
Mirtazapin
Mirtazapina
Mirtazapina [INN-Spanish]
Mirtazapine
|
Mirtazapine [Usan:Ban:Inn]
Mirtazapinum
Mirtazapinum [INN-Latin]
Mirtazepine
Mirtazon
Mundogen brand OF mirtazapine
Norset
ORG-3770
ORG-3770|Remeron®
Organon brand OF mirtazapine
Promyrtil
Reflex
Remergil
Remergon
Remeron
REMERON SOLTAB
Rexer
Zispin
|
|
47 |
|
Mazindol |
Approved, Investigational |
Phase 2 |
|
22232-71-9 |
4020 |
Synonyms:
[<sup>3</sup>H]-mazindol
42-548
AN-448
Diestet
Mazanor
Mazanor®|Sanorex®
MAZINDOL
MAZINDOL CIV
Mazindol medix brand
Mazindol novartis brand
Mazindol searle brand
Mazindol wyeth brand
Mazindole
|
MAZINDOLO
MAZINDOLUM
Medix brand OF mazindol
Novartis brand OF mazindol
SAH-42548
Sanjorex
Sanorex
Searle brand OF mazindol
Solucaps
Teronac
Teronak
Wyeth brand OF mazindol
|
|
48 |
|
Flecainide |
Approved, Withdrawn |
Phase 2 |
|
54143-55-4 |
3356 |
Synonyms:
(+-)-Flecainide
(±)-flecainide
3m Brand OF flecainide acetate
Acetate, flecainide
Alphapharm brand OF flecainide acetate
Alpharma brand OF flecainide acetate
Apocard
CCRIS 313
Flecadura
Flecaine
Flecainid isis
Flecainida
Flecainida [INN-Spanish]
FLECAINIDE
Flécaïnide
Flecainide acetate
Flecainide monoacetate
Flecainide monoacetate, (+-)-isomer
|
Flecainide monoacetate, (R)-isomer
Flecainide monoacetate, (S)-isomer
Flecainide, (R)-isomer
Flecainide, (S)-isomer
Flecainide, 5-HO-N-(6-oxo)-derivative
Flecainide, 5-HO-N-(6-oxo)-derivative, (+-)-isomer
Flecainid-isis
Flecainidum
Flecainidum [INN-Latin]
Flecatab
Merck dura brand OF flecainide acetate
N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
Riker brand OF flecainide acetate
Tambocor
Tambocor®
THN-102 COMPONENT FLECAINIDE
United drug brand OF flecainide acetate
|
|
49 |
|
Dextroamphetamine |
Approved, Illicit, Investigational |
Phase 2 |
|
51-64-9, 300-62-9 |
5826 3007 |
Synonyms:
(±)-amphetamine|Amphetamine Sulfate®|DL-amphetamine
(+)-(S)-Amphetamine
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+-)-alpha-Methylphenylethylamine
(+)-alpha-methylphenylethylamine|d-amphetamine|Dexadrine®|dextroamphetamine|Dextrostat®|S(+)amphetamine
(+)-a-Methylphenethylamine
(+)-a-Methylphenylethylamine
(+)-Amphetamine
(+)-phenaminum
(+)-Α-methylphenethylamine
(+)-Α-methylphenylethylamine
(+/-)-benzedrine
(+/-)-beta-phenylisopropylamine
(+/-)-desoxynorephedrine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(AlphaS)-alpha-methylbenzeneethanamine
(AlphaS)-a-methylbenzeneethanamine
(AlphaS)-α-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-(+)-b-Phenylisopropylamine
(S)-(+)-Β-phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-Phenyl-2-propylamine
(S)-alpha-Methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(S)-a-Methylbenzeneethanamine
(S)-Amphetamine
(S)-Α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
[1-(3-Methoxyphenyl)-2-propyl]amine
1-Methyl-2-phenylethylamine
1-Phenyl-2-aminopropane
3-Methoxy-a-methylbenzeneethanamine
3-Methoxyamphetamine
3-Methoxyphenylisopropylamine
Actedron
Adipan
Adzenys
ADZENYS ER
ADZENYS XR-ODT
Allodene
alpha-Methylbenzeneethaneamine
Amfetamin
Amfetamina
Amfetamine
Amfetaminum
Amphetamine
AMPHETAMINE RESIN COMPLEX
Amphetamine sulfate
Amphetamine sulfate (2:1)
Amsustain
Anorexide
Anorexine
Benzebar
Benzedrine
Benzolone
beta-Aminopropylbenzene
beta-Phenylisopropylamin
beta-Phenyl-isopropylamine
Celltech brand OF dextroamphetamine sulfate
Centramina
Curban
D Amphetamine
D Amphetamine sulfate
D-(+)-amphetamine
D-(s)-amphetamine
D-1-Phenyl-2-aminopropan
d-1-Phenyl-2-aminopropan [German]
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-alpha-methylphenethylamine
D-am
D-Amphetamine
D-Amphetamine sulfate
Dephadren
Desamfetamina
Desoxyn
Desoxynorephedrin
Desoxynorephedrine
Dexacaps
Dexadrine
Dexamfetamina
|
Dexamfetamina [inn-spanish]
Dexamfetamine
Dexamfetaminum
Dexamfetaminum [inn-latin]
DEXAMPEX
Dexamphetamine
Dexamphetaminum [inn-latin]
Dexanfetamina
Dexanfetamina [inn-spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
Dextro amphetamine
Dextro amphetamine sulfate
Dextroamphetamine
Dextro-amphetamine
DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine sulfate
Dextro-amphetamine sulfate
DextroStat
DL-1-Phenyl-2-aminopropane
DL-alpha-Methylphenethylamine
DL-Amphetamine
DL-Benzedrine
Dyanavel
DYANAVEL XR
Elastonon
Fenamin
Fenamine
Fenylo-izopropylaminyl
FERNDEX
Finam
GlaxoSmithKline brand OF dextroamphetamine sulfate
Isoamycin
Isoamyne
Isomyn
L Amphetamine
L-Amphetamine
Levo amphetamine
Levoamphetamine
Levo-amphetamine
Mallinckrodt brand OF dextroamphetamine sulfate
Mecodrin
Methampex
Methamphetamine HCL
Miquel brand OF amfetamine sulfate
m-Methoxy-a-methylphenethylamine
m-Methoxyamphetamine
Mydrial
Norephedrane
Novydrine
NSC-27159
NSC-73713
Oktedrin
Ortedrine
Oxydess
Paredrine
Pasadena brand OF dextroamphetamine
Percomon
Phenamine
Phenedrine
Phenopromin
Phenylisopropylamine
Profamina
Propisamine
Psychedrine
rac-(2R)-1-phenylpropan-2-amine
rac-amphetamine
Raphetamine
Rhinalator
S(+)-amphetamine
Shire brand OF dextroamphetamine sulfate
Simpatedrin
Simpatina
Sulfate, amphetamine
Sulfate, dextroamphetamine
Sympamin
Sympamine
Sympatedrine
Thyramine
Vortech brand OF dextroamphetamine sulfate
Weckamine
α-methylbenzeneethaneamine
α-methylphenethylamine
β-aminopropylbenzene
β-phenylisopropylamine
|
|
50 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
6-O-METHYL ERYTHROMYCIN
6-O-Methylerythromycin
6-O-Methylerythromycin a
A-56268
ABBOTT-56268
Biaxin
BIAXIN XL
BIAXIN XL PAC
CAM
CLA
CLARIE XL
CLARITHROMYCIN
CLARITHROMYCIN EXTENDED RELEASE
CLARITHROMYCIN IDENTITY
Clarithromycina
Clarithromycine
|
Clarithromycinum
Claritromicina
CLAROSIP
Clathromycin
FEBZIN XL
KLARICID
KLARICID 500
KLARICID ADULT
KLARICID I.V.
KLARICID PAED
KLARICID XL
MYCIFOR XL
PREVPAC
TE-031
XETININ XL
ZECLAR
|
|
Interventional clinical trials:
(show top 50)
(show all 127)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study |
Unknown status |
NCT02385656 |
Phase 4 |
Modafinil |
2 |
Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea |
Completed |
NCT00711516 |
Phase 4 |
Armodafinil;Placebo |
3 |
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function |
Completed |
NCT04789174 |
Phase 4 |
Solriamfetol;Placebo |
4 |
TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence. |
Completed |
NCT00731770 |
Phase 4 |
Advair 250;Placebo- matched;Placebo;Advair 250 - matched |
5 |
Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness |
Completed |
NCT00127348 |
Phase 4 |
|
6 |
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder |
Completed |
NCT01080807 |
Phase 4 |
Armodafinil;Matching Placebo |
7 |
A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease |
Completed |
NCT04870372 |
Phase 4 |
Selegiline |
8 |
A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi® (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi® |
Completed |
NCT05008341 |
Phase 4 |
Solriamfetol 150 mg Oral Tablet |
9 |
Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder |
Recruiting |
NCT04788953 |
Phase 4 |
Solriamfetol Oral Tablet;Placebo |
10 |
Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study |
Terminated |
NCT02473562 |
Phase 4 |
Varenicline;Placebo (for varenicline) |
11 |
The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study |
Completed |
NCT03682185 |
Phase 3 |
|
12 |
A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy |
Completed |
NCT02720744 |
Phase 3 |
FT218;Placebo |
13 |
A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder |
Completed |
NCT00758498 |
Phase 3 |
armodafinil;placebo |
14 |
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease |
Completed |
NCT00459420 |
Phase 2, Phase 3 |
Caffeine 100-200 mg BID;placebo |
15 |
Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness |
Completed |
NCT02739568 |
Phase 3 |
Pitolisant (BF2.649);Placebo |
16 |
A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase |
Completed |
NCT01066442 |
Phase 3 |
BF2.649 (Pitolisant) |
17 |
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy |
Completed |
NCT00066170 |
Phase 3 |
Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo) |
18 |
Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT01638403 |
Phase 3 |
BF2.649;Vigil;palcebo |
19 |
BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS) |
Completed |
NCT01071876 |
Phase 3 |
BF2.649;Placebo |
20 |
Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy |
Completed |
NCT01067235 |
Phase 3 |
BF2.649;BF2.649 add on Modafinil |
21 |
A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase |
Completed |
NCT01036139 |
Phase 3 |
BF2.649 (pitolisant) |
22 |
Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT01067222 |
Phase 3 |
BF2.649;Modafinil;Placebo |
23 |
A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) |
Completed |
NCT00228553 |
Phase 3 |
Armodafinil 100 to 250 mg/day |
24 |
A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome |
Completed |
NCT00228566 |
Phase 3 |
Armodafinil |
25 |
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension |
Completed |
NCT03533114 |
Phase 3 |
JZP-258;Placebo Oral Solution |
26 |
A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder |
Completed |
NCT00080288 |
Phase 3 |
Armodafinil 150 mg/day;Placebo |
27 |
Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy |
Completed |
NCT01072968 |
Phase 3 |
BF2.649;Placebo |
28 |
An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) |
Completed |
NCT01399606 |
Phase 3 |
BF2.649 |
29 |
A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia |
Completed |
NCT02151253 |
Phase 2, Phase 3 |
Armodafinil;Placebo |
30 |
A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. |
Completed |
NCT01800045 |
Phase 3 |
Pitolisant;Placebo |
31 |
Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 |
Completed |
NCT01421992 |
Phase 2, Phase 3 |
Methylphenidate;Placebo |
32 |
A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy |
Recruiting |
NCT05059223 |
Phase 3 |
AXS-12 (reboxetine);Placebo |
33 |
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia |
Recruiting |
NCT05156047 |
Phase 3 |
Pitolisant Oral Tablet;Placebo oral tablet |
34 |
A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia |
Recruiting |
NCT03597555 |
Phase 2, Phase 3 |
Sodium Oxybate Oral Solution 500 MG/ML;Placebos |
35 |
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea |
Recruiting |
NCT05223166 |
Phase 3 |
Pitolisant;Placebo oral tablet |
36 |
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR |
Active, not recruiting |
NCT04451668 |
Phase 3 |
FT218 |
37 |
A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy |
Enrolling by invitation |
NCT05113745 |
Phase 3 |
AXS-12 (reboxetine);Placebo |
38 |
An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 |
Enrolling by invitation |
NCT05458128 |
Phase 3 |
pitolisant |
39 |
Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness |
Withdrawn |
NCT02978651 |
Phase 3 |
Pitolisant (BF2.649);Placebo Oral Tablet |
40 |
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia |
Unknown status |
NCT03542851 |
Phase 2 |
Pentetrazol (PTZ);Placebo oral capsule |
41 |
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness |
Completed |
NCT00401284 |
Phase 2 |
EVT 201 |
42 |
A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease |
Completed |
NCT00641186 |
Phase 2 |
sodium oxybate |
43 |
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy |
Completed |
NCT01681121 |
Phase 2 |
ADX-N05;Placebo |
44 |
Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD) |
Completed |
NCT00642928 |
Phase 2 |
Placebo;BF 2.649 5 mg;BF 2.649 10 mg;BF 2.649 20 mg;BF 2.649 40 mg |
45 |
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness |
Completed |
NCT03037203 |
Phase 2 |
JZP-110 |
46 |
Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder |
Completed |
NCT00385437 |
Phase 2 |
Mirtazapine Treatment |
47 |
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy |
Completed |
NCT04923594 |
Phase 2 |
mazindol extended release;Placebo |
48 |
Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD). |
Completed |
NCT03194217 |
Phase 2 |
BEN-2001;Placebo |
49 |
Clarithromycin for the Treatment of Hypersomnia |
Completed |
NCT01146600 |
Phase 2 |
Clarithromycin followed by placebo;Placebo then Clarithromycin |
50 |
Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo |
Completed |
NCT01620554 |
Phase 2 |
BF2.649;Placebo |
|